Deep Dives
Contributor since: 2012
Latest Articles
Pssstt! Pfizer Is Not Executing And Is Overvalued
No Major Concerns With HCA's Preliminary Numbers
Rite Aid Reports Earnings Surprise As Revenues Continue To Slide
FDA Designation May Accelerate Palbociclib Timeline But Not Increase Approval Probability
Rite Aid Sales Continue To Erode
A Critical Analysis Of Pfizer's Pipeline, Earnings And Valuation
Walgreen's Strong March Is Business As Usual
What's Next For Cardinal Health?
Walgreen Offers Surprises On 2 Fronts
We Hate To Ring The Bell But These Pharmacy Stocks Appear Overvalued
Pfizer Gains Notable Win And A Loss In Recent Pipeline Updates
Rite Aid Increasingly Inconsequential With February Sales Figures
Celebrex Ruling Is A Windfall For Pfizer
Pfizer's Stake In HIV Breakthrough
Walgreen Maintains Momentum With February Sales
Pfizer's Cash Position Is Signaling Activity
Walgreen Catalysts Missed By Wall Street
HCA Secondary Offering Is Largely A Non-Event
Pfizer's Increasing Cash May Signify More Repurchases Or A One-Time Dividend
HCA's Exceptional Q4 Execution
Walgreen's January Sales Explode But Rite Aid Flat
HCA Holdings Perfect Confluence For Fiscal 4Q12
Pfizer Surprises But Outlook Remains Uninspiring
Pfizer's Post-2012 View Remains Void Of Necessary Catalysts